Every 424B that BridgeBio Oncology Therapeutics, Inc (BBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBOT filings page.
BridgeBio Oncology Therapeutics, Inc. filed a prospectus supplement covering the resale of 63,054,549 shares of common stock by selling securityholders and incorporating its latest quarterly report for the period ended June 30, 2026. The stock trades on Nasdaq under the symbol BBOT; the August 11, 2026 closing price was $9.20 per share.
As of June 30, 2026, the company reported $376.7 million in total assets, including $344.1 million in cash, cash equivalents, and marketable securities, and stockholders’ equity of $323.1 million. It recorded a net loss of $56.5 million for the quarter and $98.6 million for the first half of 2026, bringing accumulated deficit to $455.1 million. Operating cash outflows were $80.3 million for the six months, and the company stated that existing cash, cash equivalents, and marketable securities are expected to fund operations for at least one year from the financial statement issuance date.
BridgeBio Oncology Therapeutics, Inc. is registering 63,054,549 shares of Common Stock for resale by selling securityholders under Prospectus Supplement No. 8 dated June 22, 2026.
The supplement attaches a Form 8-K reporting governance items from the June 16, 2026 annual meeting, including director election results, ratification of Deloitte & Touche LLP, and that 80,112,725 shares were entitled to vote at the meeting with 48,344,441 shares present or represented by valid proxy. The supplement updates and supplements the Prospectus dated September 10, 2025.
Registration of 63,054,549 shares of Common Stock by the Selling Securityholders. This Prospectus Supplement No. 7 to the Prospectus (Registration No. 333-289940) registers 63,054,549 shares of common stock for resale by selling holders and attaches the Company’s Form 10-Q for the quarterly period ended March 31, 2026.
The supplement updates the Prospectus and should be read with it. The attached Form 10-Q reports a net loss of $42.1 million for the three months ended March 31, 2026 and cash, cash equivalents, and marketable securities of approximately $388.9 million as of March 31, 2026. Shares outstanding were 80,107,104 as of May 7, 2026.
BridgeBio Oncology Therapeutics, Inc. is registering 63,054,549 shares of Common Stock for resale by named selling securityholders under a shelf prospectus.
The prospectus states the company will not receive proceeds from these resales except for cash received upon exercise of 1,907,207 Options. The registration satisfies contractual registration rights and permits sales in varied methods and prices.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a Prospectus Supplement No. 6 dated April 29, 2026. The supplement attaches a Form 8-K that discloses a Board and CEO succession and a consulting agreement with former director Dr. Eli Wallace.
The Form 8-K states Pedro J. Beltran, Ph.D. succeeded Dr. Wallace as President and Chief Executive Officer effective April 20, 2026, and the Company entered a consulting agreement effective April 21, 2026 for a twelve-month term that provides for continued vesting of Dr. Wallace’s outstanding equity awards and severance rights under the Company’s Executive Severance Plan.
BridgeBio Oncology Therapeutics, Inc. filed Prospectus Supplement No. 5 registering 63,054,549 shares of Common Stock for resale by the selling securityholders. The supplement incorporates a Form 8-K reporting leadership changes: Pedro Beltran, Ph.D. was appointed President and Chief Executive Officer and joined the Board; Idan Elmelech was appointed Chief Operating Officer and named principal financial officer; Uneek Mehra will depart as CFO with last day April 30, 2026, and Marc Cobo was named principal accounting officer. The supplement references an attached press release and existing executive indemnification and severance plan exhibits.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a prospectus supplement dated March 26, 2026. The supplement amends the Form S-1 prospectus dated September 10, 2025 and attaches a Form 8-K reporting a board appointment.
The prospectus supplement states the resale is by selling securityholders (not an issuer primary sale); the company will not receive proceeds from these resales. The attached Form 8-K discloses the appointment of Peter Lebowitz, M.D., Ph.D. to the Board and a one-time option grant of 63,350 shares at an exercise price of $8.72 per share.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under Prospectus Supplement No. 3. This supplement, dated March 6, 2026, attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates the base prospectus dated September 10, 2025.
Shares outstanding were 80,032,823 as of March 2, 2026, reported in the Form 10-K; the supplement states the March 5, 2026 closing Nasdaq price of $9.89 per share.